Overexpression of Bcl-2, SOCS 1, 3 and Cdh 1, 2 are associated with the early neoplasic changes in modified 4-nitroquinoline 1-oxide-induced murine oral cancer model

Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
Adriana Alicia Cabrera OrtegaLuis C Spolidorio

Abstract

The objective was to assess histopathological changes and the expression of proliferating cell nuclear antigen (PCNA), Bcl-2, suppressor of cytokine signaling (SOCS) 1 and 3, Vimentin, TWIST1, and Cdh 1 and 2 in early stages of experimental oral carcinogenesis process using a shorter period of exposure to 4-nitroquinoline oxide (4-NQO) model. In this study, 20 rats were divided into control group (n = 10), sacrificed on the first day of the experiment, and experimental group (n = 10) treated with 50 ppm of 4-NQO solution dissolved in drinking water for 8 and 12 weeks. The histological sections were stained with H&E or subjected to immunohistochemistry for detecting PCNA, Bcl-2, SOCS 1 and 3, and STAT 3. Some specimens were used for verification of Vimentin expression, Cdh 1, Cdh 2, and TWIST1 by RT-qPCR. At both 8 and 12 weeks, morphological changes occurred mainly in the posterior portion of the tongue and were limited to the epithelial tissue, including moderate to severe dysplasia at 8 weeks, and severe dysplasia with exacerbation of atypical cells at 12 weeks. Expression of SOCS 1 and 3 increased from 8 to 12 weeks (P < 0.05), whereas STAT 3 expression was reduced mainly at 12 weeks (P < 0.05) in comparison with the control...Continue Reading

References

Feb 1, 1995·International Journal of Oral and Maxillofacial Surgery·J M NautaA Vermey
Feb 12, 1998·Oral Oncology·I van der WaalL E Smeele
Jul 31, 2003·British Journal of Cancer·M RaccurtM J Waters
Nov 4, 2005·Oral Oncology·B MognettiG N Berta
Nov 17, 2005·Proceedings of the National Academy of Sciences of the United States of America·Akihiro KimuraTadamitsu Kishimoto
Nov 29, 2005·International Journal of Experimental Pathology·Daniel A RibeiroMariângela E A Marques
Feb 2, 2006·Oral Oncology·Deepak Kanojia, Milind M Vaidya
Mar 21, 2006·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Antonia SiogaKostantinos Antoniades
Sep 23, 2008·Oral Oncology·Saman Warnakulasuriya
Oct 24, 2009·Nature Reviews. Cancer·Hua YuRichard Jove
Nov 3, 2009·Trends in Immunology·Douglas C Palmer, Nicholas P Restifo
Apr 8, 2010·International Journal of Oncology·John C CooperChao-Lan Yu
Jan 31, 2012·Journal of Molecular Histology·Juliana G CarvalhoDaniel A Ribeiro
Jan 2, 2013·Frontiers in Bioscience (Scholar Edition)·Zoran Culig
Feb 26, 2013·British Journal of Haematology·Ommoleila MolaviRaymond Lai
Apr 23, 2013·Biochimica Et Biophysica Acta·Zakir Khan, Prakash S Bisen
Sep 27, 2013·JAK-STAT·Kyoko Inagaki-OharaAkihiko Yoshimura
Oct 2, 2013·Proceedings of the National Academy of Sciences of the United States of America·Yuxin WangGeorge R Stark
Jan 15, 2014·Asian Pacific Journal of Tropical Medicine·Ge-Liang LiuYun-Zhao Lin
Apr 8, 2014·Cellular and Molecular Life Sciences : CMLS·Julhash U KaziLars Rönnstrand
Aug 13, 2015·Journal of Clinical and Diagnostic Research : JCDR·Chandrashekar PoosarlaMurali Sundar

❮ Previous
Next ❯

Related Concepts

Related Feeds

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Related Papers

Experimental and Toxicologic Pathology : Official Journal of the Gesellschaft Für Toxikologische Pathologie
Eliana Maria MinicucciDaisy M F Salvadori
© 2022 Meta ULC. All rights reserved